乳腺癌中的血清p53抗体。

Serum p53 antibody in breast cancer.

作者信息

Yamamoto Shinya, Chishima Takashi, Adachi Shouko, Harada Fumi, Toda Youko, Arioka Hitoshi, Hasegawa Naoki, Kakuta Yukio

机构信息

Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.

出版信息

Cancer Biomark. 2014;14(4):203-6. doi: 10.3233/CBM-140396.

DOI:10.3233/CBM-140396

PMID:24934362

Abstract

BACKGROUND

The significance of the measurement of anti-p53 antibodies in serum remains undisclosed. The aim of this study was to assess anti-p53 antibodies in the serum of patients with breast cancer, and correlate these results with various clinicopathologic parameters.

METHODS

We analyzed serum anti-p53 antibody levels in 124 patients with breast cancers and 7 patients with benign disease between April 2012 and March 2013, as well as levels of serum carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3.

RESULTS

Twenty-two of 124 patients with breast cancer had an increased concentration of anti-p53 antibodies. By distribution of clinical stage, in stage 0-II the positive ratio of anti-p53 antibodies was significantly higher than that of CEA (p=0.03) and CA15-3 (p=0.01). There was a significant correlation between anti-p53 antibodies and family history (p=0.03). Triple-negative cancer also showed a significant correlation with anti-p53 antibodies (p=0.007). In patients with multiple and/or bilateral breast cancer, the level of anti-p53 was significantly higher than in unilateral breast cancer (62.5% vs 14.7%, p=0.004).

CONCLUSION

Measurement of anti-p53 antibodies is useful for the prevention of oversight in the evaluation of multiple and/or bilateral breast cancer.

摘要

背景

血清中抗 p53 抗体检测的意义尚未明确。本研究旨在评估乳腺癌患者血清中的抗 p53 抗体，并将这些结果与各种临床病理参数相关联。

方法

我们分析了 2012 年 4 月至 2013 年 3 月期间 124 例乳腺癌患者和 7 例良性疾病患者的血清抗 p53 抗体水平，以及血清癌胚抗原（CEA）和癌抗原（CA）15-3 的水平。

结果

124 例乳腺癌患者中有 22 例抗 p53 抗体浓度升高。按临床分期分布，在 0-II 期，抗 p53 抗体的阳性率显著高于 CEA（p = 0.03）和 CA15-3（p = 0.01）。抗 p53 抗体与家族史之间存在显著相关性（p = 0.03）。三阴性乳腺癌也与抗 p53 抗体显示出显著相关性（p = 0.007）。在多灶性和/或双侧乳腺癌患者中，抗 p53 水平显著高于单侧乳腺癌患者（62.5% 对 14.7%，p = 0.004）。